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? Falls and fractures
Over 90 % of fractures occur after a fall and fall rates increase
with age and poor muscle strength or function [1]. Thus, a
benefit of vitamin D on both fall and fracture prevention is of
significant clinical importance. In humans, several lines of
evidence support a role of vitamin D in muscle health. First,
proximal muscle weakness is a prominent feature of the clini-
cal syndrome of vitamin D deficiency [2]. Vitamin D defi-
ciency myopathy includes proximal muscle weakness, diffuse
muscle pain, and gait impairments such as waddling way of
walking [3]. Second, VDR is expressed in human muscle tis-
sue [4], and VDR activation may promote de novo protein
synthesis in muscle [5]. Finally, suggesting a role of vitamin
D in muscle development, mice lacking the VDR show a skel-
etal muscle phenotype with smaller and variable muscle fibers
[6, 7].
? Evidence from double-blind randomized
controlled trials of oral vitamin D supple-
mentation in seniors age 65 and older
(fall and fracture prevention)
Two 2009 meta-analyses of double-blind randomized control-
led trials came to the conclusion that vitamin D reduces the
risk of falls by 19 % [8], the risk of hip fracture by 18 % and
the risk of any non-vertebral fracture by 20 % [9], however
this benefit was dose-dependent. Fall prevention was only
observed in trials with a treatment dose of at least 700 IU vita-
min D per day, and fracture prevention required a received
dose (treatment dose*adherence) of more than 400 IU vitamin
D per day. Any lower dose did not reduce fracture or fall risk,
while the benefit of fall prevention and fracture prevention
was present in all subgroups of the senior population at the
higher dose of vitamin D. The primary use of received dose
(dose*adherence) as opposed to treatment dose from double-
blind RCTs allowed for the assessment of anti-fracture effi-
cacy by a dose that accounts for the low adherence in several
recent large trials [10, 11].
The 2009 meta-analysis on fall prevention included 8 double-
blind RCTs with predefined fall assessment throughout the
Abstract: Several recent meta-analyses have
addressed the benefit of vitamin D on fracture
reduction with conflicting findings. This article
will first summarize anti-fracture efficacy from
double-blind randomized trials of oral vitamin D
supplementation. Then, this article will address
why meta-analyses with alternative approaches,
extending to open design trials and trials that
tested intra-muscular vitamin D, have reported
differential findings.
Finally, as vitamin D modulates fracture risk in
two ways, by decreasing falls and increasing
bone density, the efficacy of vitamin D on fall
prevention will be reviewed, and the optimal 25-
hydroxyvitamin D level to achieve these ben-
efits, will be suggested in this context. J Miner
Stoffwechs 2010; 17 (Suppl 1): 34– 8.
trial period (n = 2426) and found significant heterogeneity by
dose (low-dose: < 700 IU per day versus higher dose: 700–
1000 IU per day; p-value 0.02) and achieved 25-hydroxyvita-
min D level (< 60 nmol/l versus  ≥ 60 nmol/l; p-value = 0.005)
[12]. Higher dose supplemental vitamin D reduced fall risk by
19 % (pooled relative risk [RR] = 0.81; 95%-CI: 0.71–0.92; n
= 1921 from seven trials) versus a lower dose did not (pooled
RR = 1.10, 95%-CI: 0.89–1.35 from 2 trials), also achieved
serum 25-hydroxyvitamin D concentrations < 60 nmol/l did
not reduce the risk of falling (pooled RR = 1.35, 95%-CI:
0.98–1.84). Notably, at the higher dose of 700–1000 IU vita-
min D, this meta-analysis documented a 38 % reduction in
the risk of falling with treatment duration of 2 to 5 months
and a sustained significant effect of 17 % fall reduction with
treatment duration of 12–36 months, and the benefit was in-
dependent of type of dwelling and age. Thus, benefits of
700–1000 IU vitamin D per day on fall prevention are rapid
and sustained and include all subgroups of the senior popu-
lation.
Further support of a dose-response relationship of vitamin D
and fall reduction comes from a multi-dose double-blind RCT
among 124 nursing home residents receiving 200, 400, 600 or
800 IU vitamin D compared to placebo over a 5 month period
[13]. Participants in the 800 IU group had a 72 % lower rate of
falls than those taking placebo or a lower dose of vitamin D
(rate ratio = 0.28; 95%-CI = 0.11–0.75) [13].
The 2009 meta-analysis on fracture prevention included 12
double-blind RCTs for non-vertebral fractures (n = 42.279)
and 8 RCTs for hip fractures (n = 40.886), and, similar to the
meta-analysis on fall prevention, it found significant hetero-
geneity for received dose of vitamin D and achieved level of
25-hydroxyvitamin D in the treatment group for hip and any
non-vertebral fractures (Fig. 1a, b) [9]. No fracture reduction
was observed for a received dose of 400 IU or less per day or
achieved 25-hydroxyvitamin D levels of less than 75 nmol/l.
Conversely, a higher received dose of 482–770 IU supple-
mental vitamin D per day reduced non-vertebral fractures by
20 % (pooled RR = 0.80; 95%-CI: 0.72–0.89; n = 33,265 from
9 trials) and hip fractures by 18 % (pooled RR = 0.82; 95%-
CI: 0.69–0.97; n = 31,872 from 5 trials). Notably, subgroup
analyses for the prevention of non-vertebral fractures with the
higher received dose suggested a benefit in all subgroups of
the older population, and possibly better fracture reduction
with D3 compared to D2, while additional calcium did not
further improve anti-fracture efficacy (Table 1).
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? Results from meta-analyses that included
double-blind and open-design trials in
their primary analysis
In August 2007, a review and meta-analysis commissioned by
the US Department of Health and Human Services (HHS) ad-
dressed the effect of vitamin D supplementation on all frac-
tures in postmenopausal women and men ages 50 and older
[14]. The pooled results for all fractures included 10 double-
blinded and 3 open design trials (n = 58.712) and did not sup-
port a significant reduction of fractures with vitamin D
(pooled odds ratio = 0.90; 95%-CI: 0.81–1.02). The report
suggested that the benefit of vitamin D may depend on addi-
tional calcium and may be primarily seen in institutionalized
individuals, which is consistent with the meta-analysis of
Boonen et al. [15].
One 2010 patient-based meta-analysis of a subgroup of 7
large trials of vitamin D included 68.500 individuals age 47
and older [16]. The authors defined alternative criteria that
permitted the inclusion of two open design trials [17, 18], one
trial with intra-muscular vitamin D [19], and 4 of the 12 dou-
ble-blind RCTs of oral vitamin D included in the 2009 meta-
analysis described above (one RCT using intermittent vitamin
D2 without calcium [20], one RCT with 400 IU vitamin D3
without calcium [21], one trial with 800 IU vitamin D3 per
day with and without calcium and less than 50 % adherence
[11], and one trial with 400 IU vitamin D with calcium [10]).
The authors did not account for adherence to treatment. Based
on these criteria, their findings showed a reduced overall risk
of fracture (hazard ratio = 0.92; 95%-CI: 0.86–0.99) and a
non-significant reduction of hip fractures (hazard ratio = 0.84;
95%-CI: 0.70–1.01) for trials that used vitamin D plus cal-
cium. Vitamin D alone, irrespective of dose, did not reduce
fracture risk. The authors concluded that vitamin D, even in a
dose of 400 IU vitamin D per day reduces the risk of fracture
if combined with calcium. Notably, this regimen was tested in
36.282 postmenopausal women in the Women’s Health Initia-
tive Trial over a treatment period of 7 years and did not reduce
the risk of fracture.
In all 3 reports reviewed under this section, heterogeneity by
dose may have been missed due to the inclusion of open de-
sign trials plus a dose evaluation that did not incorporate ad-
herence. Biologically, the exclusion of heterogeneity by
dose seems implausible even if a formal test of heterogeneity
is not statistically significant. A dose-response relationship
between vitamin D and fracture reduction is supported by
epidemiologic data showing a significant positive trend be-
tween serum 25(OH)D concentrations and hip bone density
[22], lower extremity strength [23, 24], and trial data for fall
prevention [8].
Factors that may obscure a benefit of vitamin D are low adher-
ence to treatment [25], low dose of vitamin D, or the use of
1a: Data points and represented trial from left to right: 340 IU = Lips [65], 376 IU =
Record [11], 380 IU = Meyer [21], 482 = WHI (study medication plus personal intake)
[10], 640 IU (D3) = Trivedi [66], 640 IU = Lyons [20], 651 IU = Dawson-Hughes [67], 664
IU = Chapuy 1992 [68], 700 IU = Pfeifer 2009 [69], 760 IU = Chapuy 2002 [70], 768 IU
= Pfeifer 2000 [71], 770 IU = Flicker [63].
1b: Data points and represented trial from left to right: 62 nmol/l = Lips [65], 62 nmol/
l = Record [11], 64 nmol/l = Meyer [21], 66 nmol/l = Pfeifer 2000 [71], 74 nmol/l =
Trivedi [66], 78 nmol/l = Chapuy 2002 [70], 80 nmol/l = Lyons [20], 84 nmol/l = Pfeifer
2009 [69], 105 nmol/l = Chapuy 1992 [68], 112 nmol/l = Dawson-Hughes [67].
Figure 1a, b: Prevention of non-vertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Triangles indicate trials with D3,
circles trials with D2. Line = Trendline. All 12 high quality trials were included for the received dose meta-regression (n = 42,279 individuals). For achieved 25(OH)D levels 2 trials
did not provide serum 25(OH)D levels measured in the study population during the trial period [63, 64]. For any non-vertebral fractures, anti-fracture efficacy increased
significantly with higher received dose (meta-regression: Beta = –0.0007; p = 0.003) and higher achieved 25-hydroxyvitamin D levels (meta-regression: Beta = –0.005; p = 0.04)
(adapted from [9]).
Table 1: Non-vertebral fracture reduction with vitamin D based
on evidence from double-blind RCTs
Subgroups by received dose Fracture
of vitamin D reduction
Pooled analysis from 3 trials with +2 % Ø
low-dose vitamin D (340–380 IU/day)
Pooled analysis from 9 trials with
higher dose vitamin D (482–770 IU/day): –20 % Sig.
– Pooled subgroup analysis from trials with
Higher dose vitamin D (482–770 IE/day):
Vitamin D2 –10 % Ø
Vitamin D3 –23 % Sig.
Age 65–74 –33 % Sig.
Age 75+ –17 % Sig.
Institutionalized 65+ –15 % Sig.
Community-dwelling 65+ –29 % Sig.
Vitamin D plus Calcium –21 % Sig.
Vitamin D main effect –21 % Sig.
Prevention of non-vertebral fractures with oral vitamin D and dose dependency: a
meta-analysis of randomized controlled trials (adapted from [9]).
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less potent D2 [26, 27]. Furthermore, open design trials [28]
may bias results towards the null because vitamin D is avail-
able over the counter.
Notably, the 2009 meta-analyses on fall [8] and fracture [9]
prevention from double-blind RCTs performed sensitivity
analyses that included 4 open-design trials for fracture pre-
vention and 3 open-design trials for fall prevention. Both
analyses found significant variation in results between open
design and double-blind trials at any dose of vitamin D, the
lower and the higher dose suggesting that trial quality intro-
duces heterogeneity.
Finally, the consistency of the results for both received dose
and achieved 25(OH)D levels in the treatment group across all
12 masked trials lends support to the presence of a dose-re-
sponse relationship between supplemental vitamin D and
fracture reduction (Fig. 1a, b).
? Optimal 25-Hydroxyvitamin D levels
for bone and muscle health
A threshold for optimal 25(OH)D and fracture and fall pre-
vention has been addressed in a recent benefit-risk analysis
[29] and is illustrated in figure 2. Based on these data, 75 or
better 100 nmol/l (30 or better 40 ng/ml) are suggested as an
optimal threshold of 25-hydroxyvitamin D for fall and frac-
ture prevention.
? Adding calcium to vitamin D
The pooled RR reduction was 21 % with or without additional
calcium for the higher dose of vitamin D in the 2009 meta-
analysis of double-blind RCTs [9]. The observed calcium-in-
dependent benefit of vitamin D on non-vertebral fracture pre-
vention at a vitamin D dose greater than 400 IU per day may
be explained by a calcium-sparing effect of vitamin D [30,
31]. This is supported by two recent epidemiologic studies
suggesting that both PTH suppression [31] and hip bone den-
sity [32] may only depend on a higher calcium intake if serum
25-hydroxyvitamin D levels are very low.
As calcium absorption is improved with higher serum 25-
hydroxyvitamin D levels [31, 33], future studies may need to
evaluate whether current calcium intake recommendations
with higher doses of vitamin D beyond 2000 IU per day are
safe or require downward adjustment [33]. If dietary calcium
is a threshold nutrient, as suggested by Dr. Heaney [34], then
that threshold for optimal calcium absorption may be at a
lower calcium intake when vitamin D supplementation is ad-
equate.
? Other potential benefits of vitamin D
supplementation
Many lines of evidence also suggest that low vitamin D status
increases the risk of colon [35] and possibly other cancers
[36], increases the risk of hypertension [37], myocardial in-
farction [38], cardiovascular [39] and overall mortality [40],
infections [41] and diabetes [42]. The development of mice
lacking the receptor for vitamin D (VDR) provided insight of
the global physiologic role of vitamin D. These mice express
phenotypes that are consistent with epidemiologic studies of
25-hydroxyvitamin D deficiency in humans [43].
? What are optimal intakes of vitamin D
for bone and muscle health?
Studies suggest that 700–1000 IU of vitamin D per day may
bring 50 % of younger and older adults up to 75–100 nmol/l
[44–46]. Thus, to bring most older adults to the desirable
range of 75–100 nmol/l, vitamin D doses higher than 700–
1000 IU would be needed. According to a recent benefit-risk
analysis on vitamin D, mean levels of 75–110 nmol/l were
reached in most RCTs with 1800 IU to 4000 IU vitamin D per
day without risk [29]. In a recent trial among acute hip frac-
ture patients, 70 % reached the 75 nmol/l threshold with 800
IU vitamin D3 per day, and 93 % with 2000 IU vitamin D3 per
day, at 12 month follow-up and with over 90 % adherence
[47].
Consistently, Heaney et al., in a study of healthy men, esti-
mated that 1000 IU cholecalciferol per day are needed during
winter months in Nebraska to maintain a late summer starting
level of 70 nmol/l, while baseline levels between 20–40 nmol/l
may require a daily dose of 2200 IU vitamin D to reach and
maintain 80 nmol/l [34, 38]. These results indicate that indi-
viduals with a lower starting level may need a higher dose of
vitamin D to achieve desirable levels, while relatively lower
doses may be sufficient in individuals who start at higher
baseline levels.
Due to seasonal fluctuations of 25(OH)D levels [49], some
individuals may be in the desirable range during summer
months. However, these levels will not sustain during the win-
ter months even in sunny latitudes [50, 51]. Thus winter sup-
plementation with vitamin D is needed even after a sunny
summer. Furthermore, several studies suggest that many older
Figure 2: Threshold for optimal fall and fracture prevention based on double-blind
randomized controlled trials.
Data points show the relative risk of falls and the relative risk of sustaining any non-
vertebral fracture from double-blind RCTs, by achieved 25-hydroxyvitamin D levels in
the treatment groups. Data was extracted from two 2009 meta-analyses [8, 9] and
summarized in a recent benefit-risk analysis of vitamin D [29]. Based on these data,
75 or better 100 nmol/l (30 or better 40 ng/ml) are suggested as an optimal threshold
of 25-hydroxyvitamin D for fall and fracture prevention.
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persons will not achieve optimal serum 25(OH)D levels dur-
ing summer months suggesting that vitamin D supplementa-
tion should be independent of season in older persons [51–
53]. Even among younger persons, the use of sunscreen or
sun-protective clothing may prevent a significant increase in
25-hydroxyvitamin D levels [53].
Most vulnerable to low vitamin D levels are older individuals
[51, 54], individuals living in northern latitudes with pro-
longed winters [49, 55], obese individuals [56], and individu-
als of all ages with dark skin pigmentation living in northern
latitudes [22, 57, 58]. Naturally high 25-hydroxyvitamin D
levels observed in healthy outdoor workers are 135 nmol/l
[59] in farmers and 163 nmol/l [60] in lifeguards. As a first
sign of toxicity, only serum 25(OH)D levels of above 220
nmol/l have been associated with hypercalcemia [61, 62].
? In summary
Based on evidence from double-blind randomized-controlled
trials, vitamin D supplementation reduces both falls and non-
vertebral fractures, including those at the hip. However, this
benefit is dose-dependent. According to two 2009 meta-
analysis of double-blind RCTs, no fall reduction was ob-
served for a dose of less than 700 IU per day, while a higher
dose of 700–1000 IU supplemental vitamin D per day reduced
falls by 19 % [12]. Similarly, no fracture reduction was ob-
served for a received dose of 400 IU or less per day, while a
higher received dose of 482–770 IU supplemental vitamin D
per day reduced non-vertebral fractures by 20 % and hip frac-
tures by 18 %. Notably, the anti-fracture benefit was present
in all subgroups of the older population and was most pro-
nounced among those community-dwelling (-29 %) and those
age 65–74 years of age (–33 %).
Consistently, fall prevention and non-vertebral fracture pre-
vention increased significantly with higher achieved 25-
hydroxyvitamin D levels in the 2009 meta-analyses. Fall pre-
vention started at 25-hydroxyvitamin D levels of 60 nmol/l
[12], while at least 75 nmol/l were required for non-vertebral
fracture prevention [9]. Optimal fall and fracture prevention
was observed with 25-hydroxyvitamin D levels of close to
100 nmol/l [29]. Given the absence of data beyond this benefi-
cial range, the recent meta-analyses do not preclude the possi-
bility that higher doses or higher achieved 25-hydroxyvitamin
D concentrations would have been even more efficient in re-
ducing falls and non-vertebral fracture.
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